Boston Sci settles more Guidant cases

How's about $45 million more? Boston Scientific says it's bolstering its fund for Guidant defibrillator patients to $240 million from the $195 million it agreed to pay in July. The new total covers more patients, too. It will settle 8,500 claims stemming from Guidant defibrillators that were recalled or subject to safety warnings before Boston Scientific bought the company in April 2006. The previous deal had involved some 4,000 claims.

The company believes this will lay to rest "substantially all" of the U.S. cases. And given that it had set aside some $732 million to cover expenses, it may have money to spare. But it has to pay its attorneys first.

- check out the release from Boston Scientific
- read the BusinessWeek report

Suggested Articles

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.

After Merck and Bayer's vericiguat scored in a heart failure trial, you'd expect potential rivals to brace themselves. Not so for Novartis'…